Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

HYMECROMONE IMPURITY B CRS (25 MG)

HYMECROMONE IMPURITY B CRS (25 MG)

NA

DISCOVER
TETRAZEPAM - REFERENCE SPECTRUM (N/A)

TETRAZEPAM - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
PROPOFOL CRS (650 MG)

PROPOFOL CRS (650 MG)

2078-54-8

DISCOVER
PROPOFOL FOR PEAK IDENTIFICATION CRS (0.1 ML)

PROPOFOL FOR PEAK IDENTIFICATION CRS (0.1 ML)

2078-54-8

DISCOVER
PROPOFOL IMPURITY J CRS (20 MG)

PROPOFOL IMPURITY J CRS (20 MG)

NA

DISCOVER
4-D-SER-GOSERELIN CRS (0.1 MG)

4-D-SER-GOSERELIN CRS (0.1 MG)

NA

DISCOVER
AMILORIDE IMPURITY A CRS (20 MG)

AMILORIDE IMPURITY A CRS (20 MG)

1458-01-1

DISCOVER
PERTUSSIS TOXIN BRP (4.17 MG)

PERTUSSIS TOXIN BRP (4.17 MG)

70323-44-3

DISCOVER
SUMATRIPTAN SUCCINATE CRS (50MG)

SUMATRIPTAN SUCCINATE CRS (50MG)

103628-48-4

DISCOVER
SUMATRIPTAN IMPURITY MIXTURE CRS (3 MG)

SUMATRIPTAN IMPURITY MIXTURE CRS (3 MG)

103628-48-4

DISCOVER
SUMATRIPTAN FOR SYSTEM SUITABILITY CRS (10 MG)

SUMATRIPTAN FOR SYSTEM SUITABILITY CRS (10 MG)

103628-48-4

DISCOVER
MORANTEL HYDROGEN TARTRATE CRS (50 MG)

MORANTEL HYDROGEN TARTRATE CRS (50 MG)

26155-31-7

DISCOVER